Skip to main content
    P

    Purple Biotech (PPBT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.68
    +0.05 (+3.07%)

    Market Cap: $2.65M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Purple Biotech (PPBT) Financials: Revenue, Profit and Cash Flow

    Updated Aug 7, 2026. Financial statements from company filings, amounts in US dollars.

    Purple Biotech reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$26.39M, operating cash flow was -$5.54M and free cash flow was -$5.54M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of $441.00K.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $27.46M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$195.80KN/A-0.1%-11374.1%-10153.0%
    Dec 2022-$910.00KN/AN/AN/AN/A
    Dec 2021-$320.00K-132.0%N/AN/AN/A
    Dec 2020$1.00M0.0%-23.7%-1333.2%-2819.5%
    Dec 2019$1.00M0.0%100.0%-715.6%-585.0%
    Dec 2018$1.00M+900.0%100.0%-782.6%-520.0%
    Dec 2017$100.00KN/A100.0%-11966.0%-12177.0%
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$195.80K-$910.00K-$320.00K$1.00M$1.00M$1.00M$100.00KN/A
    Cost of revenue$204.61K$186.00K$196.00K$120$55$236.65K$80N/AN/AN/A
    Gross profit-$204.61K-$186.00K-$196-$120-$55-$236.65K$999.92K$1.00M$100.00KN/A
    Research and development$3.73M$7.62M$17.03M$16.32M$11.83M$7.29M$2.28M$5.27M$4.64M$4.18M
    Operating income-$27.46M-$11.01M-$22.27M-$22.60M-$17.93M-$13.33M-$7.16M-$7.83M-$11.97M-$7.18M
    Net income-$26.39M-$7.24M-$19.88M-$21.67M-$18.38M-$28.20M-$5.85M-$5.20M-$12.18M-$12.13M
    EBITDA-$26.25M-$7.05M-$19.72M-$21.49M-$17.52M-$13.10M-$6.14M-$5.55MN/A-$7.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Gross profitN/A-$64.82K-$53.33K-$58.27K-$48.01K-$44.77K-$40.00K-$49.00K-$49.00KN/A-$48.52K-$50.00K
    Operating income-$1.30M-$2.25M-$23.45M-$1.37M-$1.24M-$1.41M-$1.02M-$2.13M-$3.46M-$4.47M-$6.33M-$5.75M
    Net income$441.00K-$86.00K-$23.55M-$1.30M-$1.08M-$453.00K-$410.00K-$663.00K-$2.40M-$3.76M-$4.88M-$5.04M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $244.00K by $8.47M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$17.57M$37.04M$44.30M$54.62M$70.20M$83.80M$14.72M$14.72M$14.18M$14.91M
    Current assets$9.87M$8.91M$15.79M$33.26M$48.47M$59.28M$8.30M$8.51M$7.98M$14.90M
    Cash and equivalents$8.72M$7.40M$14.49M$15.03M$10.89M$11.25M$4.38M$5.16M$3.95M$6.76M
    Total liabilities$7.91M$4.13M$10.01M$7.52M$5.09M$4.05M$3.86M$3.72M$5.59M$1.53M
    Short-term debt$244.00K$183.00K$188.00K$194.00K$199.00K$207.00K$195.00KN/A$1.75MN/A
    Shareholder equity$9.71M$32.86M$34.21M$46.91M$64.83M$79.39M$10.42M$10.52M$7.31M$13.38M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$14.17M$14.42M$17.57M$39.06M$34.38M$35.59M$37.04M$35.10M$36.06M$39.86M$44.30M$45.27M
    Total liabilities$1.95M$4.75M$7.91M$6.25M$2.33M$2.90M$4.13M$5.64M$6.69M$8.77M$10.01M$6.55M
    Cash and equivalents$5.24M$5.57M$8.72M$9.59M$4.74M$5.77M$7.40M$5.44M$6.52M$9.98M$14.49M$15.10M
    Shareholder equity$12.27M$9.72M$9.71M$32.77M$32.01M$32.65M$32.86M$29.41M$29.32M$31.02M$34.21M$38.60M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$5.54M-$14.37M-$19.93M-$16.73M-$15.25M-$12.09M-$5.58M-$8.48M-$8.63M-$6.26M
    Capital expenditures$3.02K$0$3.00K$228.00K$115.00K$156.00K$11.00K$16.00K$13.00K$10.00K
    Free cash flow-$5.54M-$14.37M-$19.93M-$16.96M-$15.37M-$12.25M-$5.59M-$8.50M-$8.64M-$6.27M
    Investing cash flow$449.54K$509.00K$13.88M$19.91M$13.41M-$49.59M-$449.00K$2.04M$2.77M-$7.91M
    Financing cash flow$6.41M$6.77M$5.45M$1.11M$1.51M$68.49M$5.23M$7.79M$3.00M$10.42M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$2.50M-$3.12M-$1.07M-$1.07M-$1.54M-$1.98M-$2.01M-$3.29M-$3.98M-$5.08M-$4.98M-$3.66M
    Capital expenditures$0$0$1.04M$1.01M$2.01K$1.95M$0$0$0$0$0$1.00K
    Free cash flow-$2.50M-$3.12M-$2.11M-$2.08M-$1.55M-$3.93M-$2.01M-$3.29M-$3.98M-$5.08M-$4.98M-$3.66M
    Last 12 quarters

    Frequently Asked Questions About PPBT

    What is Purple Biotech's annual revenue?

    Purple Biotech reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Purple Biotech profitable?

    No. Purple Biotech reported net income of -$26.39M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PPBT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$5.54M minus capital expenditures of $3.02K produced free cash flow of -$5.54M.

    How much debt does Purple Biotech have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $244.00K and cash and equivalents of $8.72M.